Likewise, for leukemia, tyrosine kinase receptors, notably BCR-ABL, are critical therapeutic targets given their involvement in the proliferation and survival of chronic myeloid leukemia (CML) cells [31]. This evidence concerns the gene NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive.